The $6.3 billion financing in 2014 was equally surprising. However, despite major setbacks, the state of the investment market appears to be gradually being controlled by financing companies, and biopharmaceutical companies will almost certainly continue to go public, which will make 2015 another strong year for IPOs. With the incredible $1.81 billion in financing for biopharmaceutical companies in the fourth quarter of 2014, any fear of a cold year after the IPO that exceeded expectations for one year has dissipated. This unexpectedly strong consolidation throughout the year made 2014 the best year for companies to list since the genomics bubble of 2000. In 2000, only US biopharmaceutical companies received $5.5 billion in financing. The $1.805 billion in the fourth quarter of 2014 dwarfed $1.44 billion in the third quarter, making the fourth quarter the second best performing quarter since the start of the biotech bull market, second only to the second quarter of $2.11 billion. Dollar. But what is most impressive is that this achievement was achieved only through the listing of 17 companies, which is slightly lower than the 24 companies in the third quarter. This suggests that although investors' candidates have declined, investors' appetite for biotechnology is still good, especially for companies like Juno. Of course, the $6.3 billion financing in 2014 was equally surprising. However, despite major setbacks, the state of the investment market appears to be gradually being controlled by financing companies, and biopharmaceutical companies will almost certainly continue to go public, which will make 2015 another strong year for IPOs. However, this article is not only to show that biopharmaceutical companies have successfully obtained large sums of money. More importantly, the trend of IPO improvement in 2014 is analyzed from the perspective of EPVantage. In the fourth quarter of 2014, companies that successfully listed on the Nasdaq, the average discount between the listing price and the IPO price was 12%, which was lower than the 15% in 2013, and 24% of the shaved head that was forced to take in 2012. The discount has been significantly improved. This trend shows that although there is still a disconnect between the prices that biopharmaceutical companies want to achieve, investors and bankers are increasingly more realistic about the value of the company. However, the above average is not the whole story; for example, the Israeli biotechnology company Vascular Biogenics has a discount of up to 57% between the listing price and the IPO price for the listing, but this discount has been offset by the most successful Juno-treated IPO this year. . Juno's successful treatment has made its listing price more than 45% of the IPO price, raising $304 million in financing demand, a figure that was only surpassed by Circassia's record $332 million in financing earlier this year. Healthy Cinnamon Rolls,Homemade Cinnamon Rolls,Cinnamon Scrolls,Vegan Cinnamon Rolls jiangmen city hongsing food co., ltd. , https://www.jmhongsing.com